Bisphosphonate therapy for osteoporosis: The long and short of it

Journal of Bone and Mineral Research

Volumn 27, Issue 2, 2012, Pages 240-242

  Compston, Juliet E ^a   Bilezikian, John P ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID;

BONE DENSITY; DRUG SAFETY; FEMALE; HIP FRACTURE; HUMAN; NOTE; OSTEOPOROSIS; POSTMENOPAUSE; VERTEBRA FRACTURE;

EID: 84856147111     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1542     Document Type: Note

References (17)

1. U.S. Food and Drug Administration. September 9, 2011: Joint Meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement [Internet]. Silver Spring (MD): U.S. Food and Drug Administration [cited 2012 Jan 3]. Available from:.
2. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E,. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007; 22 (10): 1479-91. (Pubitemid 351229318)
3. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M;, American Society for Bone and Mineral Research. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25 (11): 2267-94.
4. Compston J,. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int. 2011; 22 (12): 2951-61.
5. Bonnick SL,. Going on a drug holiday?. J Clin Densitom. 2011; 14: 377-83.
6. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR,. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006; 296 (24): 2927-38. (Pubitemid 46021497)
7. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ,. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280: 2077-82. (Pubitemid 29014065)
8. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD,. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282: 1344-52. (Pubitemid 29483192)
9. Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM;, FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010; 25 (5): 976-82.
10. Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A,. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008; 19 (3): 365-72. (Pubitemid 351199181)
11. Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A,. Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab. 2011; 96: 3367-73.
12. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RLM, Tan M, Ruzycky ME, Su G, Eastell R,. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomised extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012; 27 (2): xxx-xxx.
13. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel R,. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci. 2010; 1218: 47-54.
14. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A,. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011; 305 (8): 783-9.
15. Schilcher J, Michaelsson K, Aspenberg P,. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011; 364 (18): 1728-37.
16. Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, Cummings SR, Black DM,. After 3 years of IV zoledronic acid administration, who is at highest risk for subsequent vertebral fractures and who should remain on treatment? J Bone Miner Res. 2011; 26(Suppl 1), Abstract No. 1248.
17. Grey A, Bolland M, Wattie D, Horne A, Gamble G, Reid IR,. Prolonged anti-resorptive activity of zoledronate: a randomized, controlled trial. J Bone Miner Res. 2010; 25 (10): 2251-5.